Camilo M Raggo

US Patent:

20070072209, Mar 29, 2007

Filed:

Jun 15, 2006

Appl. No.:

11/455281

Inventors:

Ashlee Moses - Portland OR, US
Klaus Frueh - Portland OR, US
Jeffrey King - Portland OR, US
James Hicks - Portland OR, US
Camilo Raggo - Portland OR, US
Jay Nelson - Tualatin OR, US

International Classification:

C12Q 1/68
G01N 33/53

US Classification:

435006000, 435007100

Abstract:

Aspects of the present invention use gene expression profiling, and gene silencing methods to identify and provide a plurality of ‘validated’ KSHV-induced cellular gene sequences and pathways useful as targets for modulation of KSHV-mediated effects on cellular proliferation and phenotype (e.g., cancer) associated with latent and lytic phases of the Kaposi's sarcoma-associated herpesvirus (KSHV; Human herpesvirus 8; HHV8) life cycle. Particular embodiments provide therapeutic compositions, and methods for modulation and treatment of KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype, comprising inhibition of KSHV-induced gene sequences or products thereof. Additional embodiments provide screening assays for compounds useful to modulate KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype. Further embodiments provide diagnostic and/or prognostic assays for KSHV infection or related conditions. Additional embodiments provide novel in vivo models for KSHV infection or related conditions. Yet further aspects provide novel methods for transforming a mammalian cell, comprising expressing, by recombinant means, a transforming amount of RDCI, Neuritin, or both, and further provide cells transformed thereby.

US Patent:

20060275769, Dec 7, 2006

Filed:

Jan 6, 2004

Appl. No.:

10/541598

Inventors:

Ashlee Moses - Portland OR, US
Klaus Fruh - Portland OR, US
Jeffrey King - Portland OR, US
James Hicks - Portland OR, US
Camilo Raggo - Portland OR, US
Jay Nelson - Portland OR, US

Assignee:

Oregon Health & Science University - Portland OR

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435006000, 435005000

Abstract:

The present invention uses gene expression profiling, and gene silencing methods to identify and provide a plurality of ‘validated’ KSHV-induced cellular gene sequences and pathways useful as targets for modulation of KSHV-mediated effects on cellular proliferation and phenotype (e.g., cancer) associated with latent and lytic phases of the Kaposi's sarcoma-associated herpesvirus (KSHV; Human herpesvirus 8; HHV8) life cycle. Particular embodiments provide therapeutic compositions, and methods for modulation of KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype, comprising inhibition of KSHV-induced gene sequences. Additional embodiments provide screening assays for compounds useful to modulate KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype. Further embodiments provide diagnostic and/or prognostic assays for KSHV infection.